Results 231 to 240 of about 721,252 (305)

pH/ROS‐Responsive Injectable Hydrogel Co‐Loaded with B7‐H3 Blocker and NETs Suppressor Boosts OSCC Synergistic Immunotherapy

Advanced Science, EarlyView.
A pH/ROS‐dual‐responsive injectable hydrogel, formed by dynamic boronic ester and Schiff base crosslinking, co‐delivers enoblituzumab (B7‐H3 blocker) and Cl‐amidine (NETs suppressor). Via localized intratumoral delivery, it synergistically reprograms the immunosuppressive tumor microenvironment, overcomes T cell infiltration barriers, restores ...
Huan Li, Yun Li, Yating Hu, Yanbing Yao, Yaodong He, Jing Li, Jiaqi Tang, Zhenyan Zhao, Yan Wang, Yulun He, Xiaolong Zhang, Xinjie Yang, Jianhua Wei   +12 more
wiley   +1 more source

Risk of malignancy of cytologic categories and post-biopsy clinical management of renal oncocytic neoplasms. [PDF]

Cancer Cytopathol
Lin X.
europepmc   +1 more source

MCV/Q, Medical College of Virginia Quarterly, Vol. 14 No. 3 [PDF]

, 1978

core   +1 more source

OCIAD2 Stabilizes Integrin β1 Signaling Through SNX17‐Mediated Endosomal Recycling to Lipid Rafts and Modulates Cisplatin Response in HNSCC

Advanced Science, EarlyView.
This study identifies OCIAD2 as a critical regulator of cisplatin resistance in HNSCC. Mechanistically, OCIAD2 stabilizes integrin β1 through a direct physical interaction and facilitates its SNX17‐dependent endosomal recycling to lipid raft microdomains. Targeting OCIAD2 disrupts integrin β1 trafficking and significantly enhances cisplatin sensitivity,
Li Cui, Shanshan Si, Min Ye, Pei Lin, Meiyan Zou, Yunfan Lin, Xu Chen, Bing Guo, Wenjuan Sun, Xinyuan Zhao   +9 more
wiley   +1 more source

Minimally Invasive Ablation Strategies for Renal Cell Carcinoma Patients Ineligible for Surgery. [PDF]

Life (Basel)
Schubert O, Sighinolfi MC, Gavi F, Panio E, Assumma S, Silvestri A, Pallotta G, Cavarra V, Russo P, Foschi N, Scarciglia E, Posa A, Maresca A, Gulino G, Cina A, Ciccarese C, Iacovelli R, Iezzi R, Rocco B.   +18 more
europepmc   +1 more source

DNMT2‐m5C‐ACLY Axis Promotes Lenvatinib Resistance in Hepatocellular Carcinoma Through Histone Acetylation‐Mediated Notch Pathway

Advanced Science, EarlyView.
Lenvatinib resistance poses a major challenge in advanced hepatocellular carcinoma (HCC). This study reveals that DNMT2 upregulation is a key driver, which stabilizes ACLY mRNA via m5C modification and activates the Notch signaling pathway. Crucially, combining ACLY inhibitors with lenvatinib overcomes resistance and suppresses tumors, offering a ...
Shiguang Yang, Jie Li, Shengwei Mao, Xuhui Zhao, Douwaner Liu, Jiafeng Chen, Jialu Fu, Yichao Bu, Xiaoling Wu, Shaoqing Liu, Qifeng Yu, Qiongzhu Dong, Zheng Tang, Yuan Fang, Yinghong Shi   +14 more
wiley   +1 more source

Multimodal artificial intelligence model based on CT for differentiating primary renal sarcomas from renal cell carcinomas: a dual-center retrospective study. [PDF]

Transl Androl Urol
Lin H, Li S, Chen Y, Chen Z, Wei J, Liu J, Guo Y, Chen W, Wang H, Luo J, Tian L, Yao H.   +11 more
europepmc   +1 more source

Glucose-transporter 1 (GLUT1) as a prognostic biomarker: evidence from 14,966 human tumors across 134 cancer types. [PDF]

BMC Cancer
Büyücek S, Möller K, Viehweger F, Schlichter R, Menz A, Luebke AM, Reiswich V, Kluth M, Hube-Magg C, Hinsch A, Lutz F, Weidemann S, Jacobsen F, Lennartz M, Dum D, Bernreuther C, Lebok P, Sauter G, Marx AH, Simon R, Fraune C, Gorbokon N, Burandt E, Minner S, Steurer S, Clauditz TS, Krech T, Chirico V.   +27 more
europepmc   +1 more source

A retroperitoneal urinoma secondary to metastatic urothelial carcinoma mimicking psoas muscle malignancy: Case Report and literature review. [PDF]

Front Oncol
Li T, Lv H.
europepmc   +1 more source